84 results about "Hidradenitis" patented technology

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

A method of treating Hidradenitis Suppurativa (HS) using a 1726 nm laser pulse that selectively targets sebum produced by the sebaceous glands.

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein (I) can inhibit TNFR1 and is expected to be useful as a therapeutic agent for treating, for example, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.The present disclosure also provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt thereof.The present disclosure also relates to a method of using the compound or a pharmaceutically acceptable salt thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, as well as a method of preparing a medicament for this purpose. [Formula 1] TIFF0007746628000195.tif82167

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I.The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

[0366] Compounds of Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the cGAS pathway, such as autoimmune disorders including Aicardi-Goutieres Syndrome (AGS), Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Scleroderma, Sjogren's Syndrome, Inflammatory Myopathies, Hidradenitis Supperativa (HS), Parkinson's Disease, Rheumatoid Arthritis, Ulcerative Colitis and Crohn's Disease, formula (II) wherein Ra, (A), R1 and R2, are defined herein.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

Provided herein are methods for treating or preventing inflammatory skin disorders, such as Hidradenitis suppurativa, by administering to a subject having or at risk of developing the inflammatory skin disorder an agent that inhibits NK cell activity.

The present invention provides compositions and methods for treating hidradenitis suppurativa (HS) or an apocrine gland infection. In one embodiment, the invention provides a method for treating HS or an apocrine gland infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I),or a pharmaceutically acceptable salt thereof, wherein R is halogen, amino, —NH(C1-C3-alkyl) or —N(C1-C3-alkyl)2 and n is 1 or 2.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of formula I is as described in the claims and the description. The aromatic ring derivative containing an amide substitution provided in the present invention is used as a novel TYK2 inhibitor, has a good TYK2 inhibitory effect, has a good therapeutic effect in an in vivo model of psoriasis and asthma animals, and has good druggability, high stability and good safety.

The present invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The present invention describes methods and uses for the treatment of hidradenitis suppurativa with an anti-interleukin 36R (anti-IL36R) antibody. Methods for determining the efficacy of an anti-IL36R antibody to treat hidradenitis suppurativa in a subject are also described.

The invention belongs to the technical field of medicines, and particularly relates to a novel amide-substituted aromatic ring derivative or pharmaceutically acceptable salt thereof, which comprises but is not limited to inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, uveitis and the like. The structure of the compound shown in the formula I is shown in the claims and the specification. As a novel TYK2 inhibitor, the amide-substituted aromatic ring derivative provided by the invention has a good TYK2 inhibition effect, has a good treatment effect in an animal in-vivo model of psoriasis and asthma, and has good druggability, high stability and good safety.

Viscoelastic coagulation monitoring systems having two glass discs mounted on flexible plastic arms for receiving a sample of blood therebetween, and an analyzer configured to measure a coagulation response of the sample of blood to determine whether the sample of blood indicates a hypercoagulable state in a HS patient are provided. The system may cause movement of a first glass disc relative to a second glass disc at a sufficient speed to cause coagulation of the sample of blood, and the analyzer may measure various parameters of the coagulation response including, e.g., Clotting Time (CT), Clot Formation Time (CFT), Alpha Angle (a-angle), Maximum Clot Firmness (MCF), Amplitude at 10 and 20 minutes (A10, A20, respectively), Lysis Index at 30 and 45 minutes (LI30 and LI45, respectively), indicative of a hypercoagulable state in a HS patient.

The present disclosure relates to methods of treating hidradenitis suppurativa with anti-IL-1β antibodies.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are NLRP3 inhibitors and may be useful in the treatment, prevention, management, improvement, control, and suppression of NLRP3-mediated diseases. The compounds of the present invention may be useful in the treatment, prevention, or management of NLRP3-mediated diseases, disorders, and conditions such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (LBD), and traumatic brain injury. (I)

Disclosed are biomarker-based methods of treatment, monitoring, and diagnosis for IL-17 dependent conditions, including hidradenitis suppurativa. The biomarker may be selected from the group consisting of IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, kits for measuring biomarkers, diagnosing and treating IL-17 dependent conditions, and identifying superresponders are also disclosed.

The invention provides certain tetrahydropyran-imidazotriazine compounds of formula I or II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I or II to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The invention provides certain difluorotetrahydropyran-imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The present invention provides the use of an IL-21 inhibitor, as well as pharmaceutical formulations, and dosage forms comprising the same for use in the treatment or prophylaxis of Hidradenitis Suppurativa (HS).

The invention provides certain dimethyltetrahydropyran-imidazotriazine compounds of formula (I) as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The present disclosure relates to methods of treating hidradenitis suppurativa in a subject comprising administering to the subject a therapeutically effective amount of lutikizumab.

The present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, which inhibits TNFR1 and is contemplated to have utility as a therapeutic agent, e.g., for the treatment of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiological central axis type spondylitis, and hidradenitis suppurativa. The invention also provides pharmaceutical compositions comprising the compounds disclosed herein, or pharmaceutically acceptable salts thereof. The present invention also relates to the use of said compounds or pharmaceutically acceptable salts thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiological axial spinal arthritis and hidradenitis suppurativa, and a method for preparing a pharmaceutical product for this purpose.

The invention provides certain tetrahydropyran-imidazotriazine compounds of formula (I) as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula (I) to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subjects with hidradenitis suppurativa. Further disclosed are T cells, and in particular, Treg cells that express these CARs. Administration of these CAR-T cells is useful in the treatment of hidradenitis suppurativa.

Disclosed in the present invention are a polymorph of a benzo[c]chroman compound, a preparation method therefor and use thereof. The present invention particularly provides a polymorph of a compound represented by formula I, a preparation method therefor and use thereof. The compound represented by formula I is used as a cathepsin C inhibitor, and a crystalline form of the compound and a pharmaceutical composition comprising the crystalline form can be used for treating asthma, obstructive pulmonary diseases, bronchiectasis, ANCA-related vasculitis, psoriasis, α1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel diseases, rheumatic arthritis, rhinosinusitis, hidradenitis suppurativa or cancers.

This disclosure provides a diagnostic method, which can be used in combination with medical intervention, that uses one or more plasma biomarkers useful for identifying subjects with hidradenitis suppurativa (HS), measures the disease severity of HS, and measures the clinical response in subjects with HS. This disclosure relates to a method for testing for hidradenitis suppurativa (HS) in a subject, comprising measuring one or more plasma biomarkers in a sample taken from the subject, wherein one or more plasma biomarkers are selected from the group consisting of IL8, IL36β, MDC, and TNFα.